INTRODUCTION Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) have been circulating worldwide since the beginning of the pandemic. Some are termed …
Summary SARS-CoV-2-neutralizing antibodies (NAbs) protect against COVID-19. A concern regarding SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we …
The severe acute respiratory coronavirus 2 (SARS-CoV-2) spike (S) protein is the target of vaccine design efforts to end the coronavirus disease 2019 (COVID-19) pandemic. Despite …
SARS-CoV-2 infection is associated with a surprising number of morbidities. Uncanny similarities with amyloid-disease associated blood coagulation and fibrinolytic disturbances …
Severe acute respiratory syndrome coronaviruses 1 (SARS-CoV) and 2 (SARS-CoV-2), including SARS-CoV-2 variants of concern, can cause deadly infections. The mortality …
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA. 2 sub- lineage has gained in proportion relative to BA. 1. Because spike (S) protein variations may …
SM Costello, SR Shoemaker, HT Hobbs… - Nature Structural & …, 2022 - nature.com
Current COVID-19 vaccines and many clinical diagnostics are based on the structure and function of the SARS-CoV-2 spike ectodomain. Using hydrogen–deuterium exchange …
To address the ongoing SARS-CoV-2 pandemic and prepare for future coronavirus outbreaks, understanding the protective potential of epitopes conserved across SARS-CoV …
A safe, effective, and scalable vaccine is needed to halt the ongoing SARS-CoV-2 pandemic. We describe the structure-based design of self-assembling protein nanoparticle …